The total revenue from branded cardiovascular drugs in 2017 is projected to be just over $40 billion. Top companies in this space are putting a heavy focus on the anti-thrombotic segment, as these drugs continue to bring in the biggest profit and dominate the cardiovascular market.
Go deeper with GlobalData
Figures ($M) represent projected 2017 global sales of cardiovascular products. Credit: GlobalData.
Bayer currently holds the top spot in the market with 2017 sales of $5.4 billion; however, Sanofi and BMS come in a close second and third with sales of $5.1 and $4.7 billion, respectively.
Overall, apart from the anticoagulants segment, companies are investing less frequently due to the heavily genericized and mature nature of the cardiovascular market. This and the high cost of drug development makes the cardiovascular market hard to penetrate, especially for smaller, less established companies.
The clear leaders in sales of cardiovascular drugs are Eliquis and Xarelto (NOACs). These two drugs currently represent over 30% of the total cardiovascular market and their shares will continue to expand.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataDespite high clinical unmet needs, this market is not expected to grow significantly in the near future, with the exception of the NOACs class.
Figures ($M) represent projected 2017 global sales. Credit: GlobalData.
Related Company Profiles
Bayer AG